Lilly pays Sitryx $50M upfront for preclinical autoimmune assets

Eli Lilly has paid Sitryx $50 million (€46 million) upfront for global rights to up to four autoimmune drugs. The deal sees Lilly commit to up to $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.